Pedzinska-Betiuk A, Modzelewska B, Kostrzewska A, Jozwik M
Department of Biophysics, Medical University of Bialystok, Poland.
J Physiol Pharmacol. 2008 Dec;59 Suppl 9:43-54.
The purpose of this study was to evaluate the effect of beta(3)-adrenoreceptor agonist, CL 316243 on human non-pregnant uterine contractility. The activity of myometrium strips was recorded by means of force transducers with digital output. Quantification of the response of myometrium strips was done by calculation of the area under the curve (AUC), as well as the amplitude and frequency of contractions. CL 316243 in a concentration - dependent manner (10(-10)-10(-4) mol/L) decreased the AUC value (logIC(50) -8.088+/-0.29; n=16). Decreased mean frequency of contractions and nearly 30% inhibition of spontaneous contractile activity were also observed. The inhibition of contractions by CL 316243 was not changed by either butoxamine (selective beta(2)-adrenoreceptor antagonist) or propranolol (beta(1)- and beta(2)-adrenoreceptor antagonist), and was partly antagonized by bupranolol (nonselective beta-adrenoreceptor antagonist), each antagonist at 10(-6) mol/L.
CL 316243 causes inhibition of spontaneous contractile activity of human non-pregnant myometrium. Our findings also indicate that CL 316243 attenuates the contractile activity of human non-pregnant myometrium by the beta(3)-adrenoreceptors activation.
本研究的目的是评估β(3)-肾上腺素能受体激动剂CL 316243对人非妊娠子宫收缩性的影响。通过带有数字输出的力传感器记录子宫肌条的活性。通过计算曲线下面积(AUC)以及收缩的幅度和频率对子宫肌条的反应进行量化。CL 316243以浓度依赖性方式(10(-10)-10(-4)mol/L)降低AUC值(logIC(50) -8.088±0.29;n = 16)。还观察到收缩的平均频率降低以及自发收缩活性受到近30%的抑制。CL 316243对收缩的抑制作用不受布托沙明(选择性β(2)-肾上腺素能受体拮抗剂)或普萘洛尔(β(1)-和β(2)-肾上腺素能受体拮抗剂)的影响,但部分被布普洛尔(非选择性β-肾上腺素能受体拮抗剂)拮抗,每种拮抗剂的浓度均为10(-6)mol/L。
CL 316243可抑制人非妊娠子宫肌层的自发收缩活性。我们的研究结果还表明,CL 316243通过激活β(3)-肾上腺素能受体减弱人非妊娠子宫肌层的收缩活性。